Literature DB >> 9724165

Intrahepatic enhanced expression of beta2-microglobulin conformational epitope in acute liver allograft rejection: evidence of modulation by glucocorticoids.

C García-Monzón1, P L Majano, J A Solís, S Rodríguez, F Colina, M López-Botet, E Moreno-González, R Moreno-Otero.   

Abstract

The mechanisms by which glucocorticoids are effective in acute liver rejection therapy are not entirely clear. The aims of this study were to characterize the intrahepatic immunological phenotype in acute liver rejection, as well as the effect of glucocorticoids on cytokine-stimulated hepatocyte cell lines. Biopsy sections from these patients were studied by immunohistochemistry. Cytokine-stimulated hepatocyte cell lines treated with glucocorticoids were evaluated by flow cytometry. The intrahepatic expression of both beta2-microglobulin conformational epitope and intercellular adhesion molecule-1 was higher in acute rejection than in resolving rejection. Interestingly, glucocorticoids were able to modulate in vitro the cytokine-induced expression of these molecules on hepatocyte cell lines. Beneficial effects of the glucocorticoid treatment appear to be associated with a modulation of a beta2-microglobulin conformational epitope and the intercellular adhesion molecule-1 on intrahepatic cellular targets in the acute rejection process.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9724165     DOI: 10.1023/a:1018835720267

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  16 in total

Review 1.  Patterns of graft rejection following liver transplantation.

Authors:  D H Adams; J M Neuberger
Journal:  J Hepatol       Date:  1990-01       Impact factor: 25.083

2.  Involvement of the CD4 molecule in a post-activation event on T cell proliferation.

Authors:  A C Carrera; F Sanchez-Madrid; M Lopez-Botet; C Bernabeu; M O De Landazuri
Journal:  Eur J Immunol       Date:  1987-02       Impact factor: 5.532

Review 3.  Liver transplantation (2).

Authors:  T E Starzl; A J Demetris; D Van Thiel
Journal:  N Engl J Med       Date:  1989-10-19       Impact factor: 91.245

4.  Liver allograft rejection. An analysis of the use of biopsy in determining outcome of rejection.

Authors:  D C Snover; D K Freese; H L Sharp; J R Bloomer; J S Najarian; N L Ascher
Journal:  Am J Surg Pathol       Date:  1987-01       Impact factor: 6.394

5.  Biopsy-directed immunosuppression following hepatic transplantation in man.

Authors:  J W Williams; T G Peters; S R Vera; L G Britt; S J van Voorst; R C Haggitt
Journal:  Transplantation       Date:  1985-06       Impact factor: 4.939

6.  Three distinct antigens associated with human T-lymphocyte-mediated cytolysis: LFA-1, LFA-2, and LFA-3.

Authors:  F Sanchez-Madrid; A M Krensky; C F Ware; E Robbins; J L Strominger; S J Burakoff; T A Springer
Journal:  Proc Natl Acad Sci U S A       Date:  1982-12       Impact factor: 11.205

7.  Increased expression of class I major histocompatibility complex antigens on hepatocytes in rejecting human liver allografts.

Authors:  S K So; J L Platt; N L Ascher; D C Snover
Journal:  Transplantation       Date:  1987-01       Impact factor: 4.939

8.  Effectiveness of histopathological diagnoses in dysfunction of hepatic transplantation. Review of 146 histopathological studies from 53 transplants.

Authors:  F Colina; M Mollejo; E Moreno; N Alberti; I García; R Gómez-Sanz; G Castellano
Journal:  Arch Pathol Lab Med       Date:  1991-10       Impact factor: 5.534

Review 9.  Hepatic allograft rejection: new developments in terminology, diagnosis, prevention, and treatment.

Authors:  R H Wiesner; J Ludwig; R A Krom; J E Hay; B van Hoek
Journal:  Mayo Clin Proc       Date:  1993-01       Impact factor: 7.616

10.  A quantitative analysis of T lymphocyte populations in human liver allografts undergoing rejection: the use of monoclonal antibodies and double immunolabeling.

Authors:  G W McCaughan; J S Davies; J A Waugh; G A Bishop; B M Hall; N D Gallagher; J F Thompson; A G Sheil; D M Painter
Journal:  Hepatology       Date:  1990-12       Impact factor: 17.425

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.